MDNA.TO (MC C$36 M) (Cash C$20 M)Cancer Play with data in Q1

MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential !

Brutally cheap and completely unknown canadian biotech stock with minimum 10 bagger potential . Positive Phase 2 results in recurrent glioblastoma which expected in Q1 2018 could lead to accelerated approval which would be a HUGE MAJOR milestones for this undiscovered low float stock . This company has brutally low valuation of only $36 million and most of that in cash $20 million which is enough untill Q1 2019 . This stock at $1.50 is a lifetime opportunity and we could see $15-20 easily on Positive 2 results and FDA approval .GL


Medicenna Therapeutics (MDNA.TO)

Market Cap C$36 Million
Cash : C$ 20 Million << enough untill Q1 2019
Price : $1.50

Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )


Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/


New Presentation
s21.q4cdn.com/710416940/files/doc_presentations/2017/Medicenna-Corporate-Presentation-Q3-2017.pdf


Fact Sheet
s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf

Insider Ownership :

Aries Biologics, Inc. 5 500 000
Rosemina Merchant 5 050 000
Fahar Merchant 5 050 000
Elizabeth Williams 5 300
Chandrakant J. Panchal, PhD 1 000
Trevor P. Wong-Chor 714